𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety of influenza vaccination: Risk–benefit evaluation

✍ Scribed by Viroj Wiwanitkit

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
132 KB
Volume
42
Category
Article
ISSN
0148-639X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunogenicity and safety of influenza v
Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease
✍ Jennifer C.C. deBruyn; Robert Hilsden; Kevin Fonseca; Margaret L. Russell; Gilaa 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 2 views

Background: Protection against vaccine-preventable diseases is important in inflammatory bowel disease (IBD) because of increased susceptibility and severity of infection with immunosuppressive therapy. However, immunosuppressive therapy may affect vaccine response. This study aimed to evaluate immu

Preparation and evaluation of a zonal pu
Preparation and evaluation of a zonal purified influenza vaccine gripax
✍ Reuven Levy; Dr. Zichria Zakay-Rones 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 492 KB

## Abstract A highly purified influenza vaccine was prepared on a large scale. The inactivated whole virus vaccine fulfills the requirements of the National Institutes of Health, Bethesda, for influenza A and B vaccines. The three strains of influenza virus, A/England/321/77, B/Hong Kong/8/73, and

Immunogenicity and safety of a novel lip
Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults
✍ Arie Ben-Yehuda; Aviva Joseph; Evelyne Zeira; Simcha Even-Chen; Igal Louria-Hayo 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

## Abstract Influenza and its complications account for substantial morbidity and mortality among young adults and especially among the elderly. In young adults, immunization provides 70–90% protection, while among the elderly the vaccine may be only 30–40% effective; hence the need for new, more i

Evaluation of properties of chitosan as
Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally
✍ Yuri Ghendon; Stanislav Markushin; Yuri Vasiliev; Irina Akopova; Irina Koptiaeva 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB

## Abstract Studies on mice showed that chitosan as an adjuvant for H5 inactivated influenza vaccines administered intramuscularly enhances significantly antibody titers and protective efficiency not only against homologous influenza viruses, but also against drift variants. Chitosan adjuvanted vac